Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Ziopharm Oncology — J.P. Morgan 39th Annual Healthcare Conference (January 2021)
23 slides from Alaunos Therapeutics's conference presentation, Jan 14, 2021
Slide 1: J.P. Morgan 39th Annual Healthcare Conference
J.P. Morgan 39th Annual Healthcare Conference January 14, 2021 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking sta
Slide 3: Agenda
01 02 03 04 Agenda Where We Are Entering The Year TCR-T Program: Our Top Priority And Opportunity Approach For Our CAR-T And IL-12 Programs 2021 Expectations
Slide 4: Agenda
01 02 03 04 Agenda Where We Are Entering The Year TCR-T Program: Our Top Priority And Opportunity Approach For Our CAR-T And IL-12 Programs 2021 Expectations
Slide 5: Ziopharm Oncology Today
Ziopharm Oncology Today Mission We develop innovative T cell-based therapies for the treatment of solid tumors, treating cancer on time, one cell at a time Long-Term Vision Distinctive commercial and clinical portfolio of immunotherapies transforming patient lives, supported by a growing body of com
Slide 6: 2021 is a Key Inflection Point for the Company
2021 is a Key Inflection Point for the Company Q4 2018 – 2020 Cell Therapy and IL-12 Focus Pursuing an independent strategy Establishing capabilities Initiating trials in prioritized areas 2015 – 2018 Cell Therapy Research Initiated Under Partner Dependent Model Pre 2015 Exploration of Small Molecul
Slide 7: Addressing Shareholder Feedback is Critically Important
Dissatisfaction with engagement and Board/management flux Concerns regarding the capital requirements of carrying three platforms forward Delays in program progress (e.g., NCI TCR-T Personalized Phase 2, CAR-T) Share price erosion Addressing Shareholder Feedback is Critically Important Shareholder F
Slide 8: We Have the Core Technology and Infrastructure to be Leaders in Cell Therapy
We Have the Core Technology and Infrastructure to be Leaders in Cell Therapy 01 02 03 04 Pioneers in non-viral gene transfer Cytokine biology expertise Strong SAB and established partnership network bring external strength Building momentum in TCR-T clinical programs Establishing infrastructure and
Slide 9: 2021 is a Year of Disciplined Strategic Focus
2021 is a Year of Disciplined Strategic Focus Strategic Filters Our distinct capabilities Balance of de-risked feasibility and innovation Direct line of sight to patient data and unmet need Assessment of resource and capital constraints Strategic Positioning TCR-T Programs: Advance clinical program
Slide 10: Agenda
01 02 03 04 Agenda Where We Are Entering The Year TCR-T Program: Our Top Priority And Opportunity Approach For Our CAR-T And IL-12 Programs 2021 Expectations
Slide 11: Neoantigens are the Blueprint for Targeting Solid Tumors
Neoantigens are the Blueprint for Targeting Solid Tumors The Right Targets Clinical Foundation Treatment Opportunity We believe over half of all cancer patients could potentially be treated by this type of immunotherapy meaning 7M+ patients suffering today could benefit in the US alone (plus 700-800
Slide 12: TCR-Based Immunotherapies Can Potentially Address Significant Patient Need Across Broad Range of Solid Tumors
TCR-Based Immunotherapies Can Potentially Address Significant Patient Need Across Broad Range of Solid Tumors Expanding Off-the-Shelf TCR Library – Q1 2021 IND On Track Personalized TCR-T Approach – Increased Complexity and Broader Applicability Potential to treat half or more of the ~1.6M annual (U
Slide 13: Pan-Cancer Neoantigen-Specific TCRs Expressed via Sleeping Beauty Transposition Lead to Tumor Cell Lysis
Pan-Cancer Neoantigen-Specific TCRs Expressed via Sleeping Beauty Transposition Lead to Tumor Cell Lysis TP53 KRAS Among the most mutated genes in human cancers Functions as a transcription factor to regulate cell division and stabilize the genome KRAS mutations are validated clinical targets Functi
Slide 14: Library Off-the-shelf and Personalized Cell Therapies
Library “Off-the-shelf” and Personalized Cell Therapies Diagnostic Pathway Treatment Pathway Genetic Screening of Tumor (incl HLA) Initial TCR Library Library Match No Existing Library Match TCR Library “off-the-shelf” Access to unique libraries (expanding through TCR hunting) – access to IP from be
Slide 15: Agenda
01 02 03 04 Agenda Where We Are Entering The Year TCR-T Program: Our Top Priority And Opportunity Approach For Our CAR-T And IL-12 Programs 2021 Expectations
Slide 16: CAR-T Innovation: Rapid Personalized Manufacturing (RPM)
CAR-T Innovation: Rapid Personalized Manufacturing (RPM) Addressing Cost And Complexity Limiting The Commercialization Of Existing CAR-T Uses Sleeping Beauty non-viral system Local, very rapid, simplified, scalable manufacturing Genetic modification of resting T cells with CAR and membrane-bound IL-
Slide 17: CD19 CAR Rapid Personalized Manufacturing (RPM) – Clinical Programs
CD19 CAR Rapid Personalized Manufacturing (RPM) – Clinical Programs A solution to cost and complexity of commercial CAR-T today with one continuous program Phase 1 Trial Initiated To Evaluate Allogeneic CD19 CAR-T Investigational treatment for patients with CD19+ leukemias and lymphomas who have rel
Slide 18: CD19 CAR Rapid Personalized Manufacturing (RPM) – Status Summary
CD19 CAR Rapid Personalized Manufacturing (RPM) – Status Summary Partnering with Tri-Arm Therapeutics via our JV Eden Biocell Female 52 years old FL Two prior lines of therapy Treated in Jul-2020 Appears well tolerated No serious CRS Male 49 years old MCL Four prior lines of therapy Treated in Aug-2
Slide 19: Development Summary For Controlled IL-12
Development Summary For Controlled IL-12 A late-stage immuno-oncology platform with >2,000+ doses of veledimex administered in >175 patients Clinical Trial Enrollment Mechanism of action enables treatment across many solid tumors as monotherapy or in combination Turning cold tumors hot improves tumo
Slide 20: Agenda
01 02 03 04 Agenda Where We Are Entering The Year TCR-T Program: Our Top Priority And Opportunity Approach For Our CAR-T And IL-12 Programs 2021 Expectations
Slide 21: Disciplined Capital Allocation Directed By Strategic Prioritization
Disciplined Capital Allocation Directed By Strategic Prioritization $135.5 million in cash and cash equivalents as of 9/30/20 $11.4 million at MD Anderson from prepayment for programs to be conducted by the Company as of 9/30/20 Sufficient to fund planned operations and execute our strategy into mid
Slide 22: Upcoming Clinical Milestones
Upcoming Clinical Milestones Library TCR-T Program* Ph 1/2 IND Clearance H1 2021 CD19 CAR-T RPM Autologous (Taiwan) Preliminary Ph 1 data H2 2021 Library TCR-T Program Ph 1 Initial Data Readout 2022 Personalized TCR-T Program (NCI) Ph 2 Patient Initiation Personalized/Next Gen TCR-T Program Ph 1 IND
Slide 23: 2021 Snapshot of Priorities
2021 Snapshot of Priorities Host R&D Day with management, Steven Rosenberg, Carl June and others in Q1 Expect to treat patients and generate RPM CD19 CAR-T Patient Data IND in Q1 2021 for Ziopharm's TCR-T Library trial to be initially undertaken at MD Anderson; First patient expected in H2 First pat
Ziopharm Oncology — J.P. Morgan 39th Annual Healthcare Conference (January 2021) on 6ix